Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing

The Central Social Insurance Medical Council (Chuikyo) on November 9 approved a throng of medicines for their reimbursement listing on November 16, with a subcutaneous auto-doser version of Skyrizi (risankizumab) carrying the largest peak sales outlook of over 30 billion...read more